Caraco Pharmaceutical gets FDA approval for generic Glucotrol

By Elaine Rigoli

Tampa, Fla., July 12 - The Food and Drug Administration has granted final approval to Caraco Pharmaceutical Laboratories, Ltd. for glipizide tablets, the generic equivalent of Pfizer's Glucotrol, an anti-diabetic drug.

Caraco said it will manufacture and market both 5 mg and 10 mg tablets.

"We are pleased to gain this approval and add this to our growing portfolio of products that we market in the U.S. Glipizide will complement our current product mix by adding another anti-diabetic to our line. We plan to launch this product to the market immediately," chief executive officer Daniel H. Movens said in a news release.

Detroit-based Caraco develops generic and private-label prescription pharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.